Intrinsic subtype and therapeutic response among HER2-positive breast tumors from the NCCTG (Alliance) N9831 trial

Journal of the National Cancer Institute

Volumn 109, Issue 2, 2017, Pages

  Perez, Edith A ^a   Ballman, Karla V ^b   Mashadi Hossein, Afshin ^c   Tenner, Kathleen S ^b   Kachergus, Jennifer M ^a   Norton, Nadine ^a   Necela, Brian M ^a   Carr, Jennifer M ^a   Ferree, Sean ^c   Perou, Charles M ^d   Baehner, Frederick ^e   Cheang, Maggie Chon U ^d,f   Thompson, E Aubrey ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c Nanostring Inc   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e Genonic Health Inc   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ADJUVANT THERAPY; ALGORITHM; ARTICLE; BASAL LIKE BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL OUTCOME; COHORT ANALYSIS; GENOMICS; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLASSIFICATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; PACLITAXEL; RECEPTOR, ERBB-2; TRASTUZUMAB; TUMOR BURDEN;

EID: 85018211128     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw207     Document Type: Article

References (13)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
2. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
3. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol. 2010;11(8):718-719; author reply 720-711.
4. Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18(16):4465-4472.
5. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22): 2783-2790.
6. Esserman LJ, Berry DA, Cheang MC, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132(3):1049-1062.
7. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
8. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology. 2014;32(33):3744-3752.
9. Perez EA, Baehner FL, Butler SM, et al. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Res. 2015;17(1):133.
10. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
11. Prat A, Bianchini G, Thomas M, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clinical cancer research: An official journal of the American Association for Cancer Research. 2014;20(2):511-521.
12. Pogue-Geile KL, Song N, Jeong JH, et al. Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology. 2015.
13. Prat A, Carey LA, Adamo B, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. Journal of the National Cancer Institute. 2014;106(8).